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Background: Mycoepoxydiene (MED) is a polyketide that can be isolated from a marine fungus and is associated
with various activities, including antitumor and anti-inflammatory functions. However, its effects on atherosclerosis
remain unknown. Macrophage-derived foam cells play crucial roles in the initiation and progression of atherosclerotic
plaques. In this study, we investigated the effects of MED on oxidized low-density lipoprotein (ox-LDL)-induced
macrophage foam cell formation and activation, and on high fat diet (HFD)-induced atherosclerosis in ApoE-deficient
(ApoE−/−) mice.
Results: Our findings show that MED could significantly inhibit ox-LDL-induced macrophage foam cell formation and
suppress the expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), which is a receptor for
ox-LDL. Additionally, MED could significantly inhibit the secretion of proinflammatory cytokines, such as tumor necrosis
factor (TNF-α), interleukin (IL)-6, and IL-1β. Mechanistically, MED inhibited NF-κB activation by blocking IκB-α degradation
and reducing NF-κB DNA binding activity. Moreover, MED dramatically reduced the occurrence of HFD-induced
atherosclerotic lesions in ApoE−/− mice.
Conclusions: Our study shows that MED can inhibit macrophage foam cell formation and activation by inhibiting NF-κB
activation, thereby protecting ApoE−/− mice from HFD-induced atherosclerosis. Our findings suggest that MED might be
a potential lead compound for the development of antiatherosclerotic therapeutics.
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Atherosclerosis, a chronic inflammatory disease that is
characterized by the accumulation of lipids and fibrous
elements that result from interactions between vascular
cells and inflammatory cells, is a leading cause of mor-
tality in developed countries [1, 2]. Studies have shown
that inflammation plays a critical role in all stages, from
initiation through progression, and ultimately drives the
thrombotic complications of atherosclerosis. Ox-LDL
plays a critical role in triggering proinflammatory and
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creativecommons.org/publicdomain/zero/1.0/activation of atherosclerosis [3, 4]. Ox-LDL is taken up
via the scavenger receptor expressed by macrophages,
which turns macrophages into lipid-laden foam cells [5].
Additionally, ox-LDL stimulates macrophages to release
proinflammatory cytokines such as IL-1β and TNF-α [6].
LOX-1, which is a lectin-like receptor for ox-LDL in
endothelial cells, smooth muscle cells, and macrophages
[7–9], plays important roles in atherosclerosis develop-
ment [10]. The binding of ox-LDL to LOX-1 leads to
ox-LDL uptake by macrophages and foam cell trans-
formation [11]. NF-κB, which is a downstream factor of
LOX-1, is a pivotal transcription factor involved in
atherosclerosis. NF-κB activation has been observed at
different stages of atherosclerosis, from plaque formation
to its destabilization and rupture [12, 13]. LOX-1 can be
dynamically up-regulated by various proinflammatory,
pro-oxidative, and mechanical stimuli [14–16]. Many
antiatherosclerotic drugs, such as stains, exert theire distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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regulation of LOX-1 expression [17, 18].
Mycoepoxydiene (MED) is a novel polyketide that can
be isolated from the marine fungus Diaporhte sp. (D.sp.)
HLY-1 and was discovered in submerged rotten leaves of
Kandelia candel in a mangrove forest in Fujian Province,
China [19]. It contains an α, β-unsaturated-lactone moiety
and an oxygen-bridged cyclooctadiene core [20]. Previous
studies have shown that MED could exert antimicrobial
and antitumor activities [19, 21]. Recently, we have
showed that MED could inhibit LPS-induced inflamma-
tory responses, ovariectomy-induced osteoporosis, and
allergic responses in mice [22–24]. In macrophages, MED
can significantly inhibit the LPS-induced expression of
proinflammatory mediators, such as TNF-α, IL-6, IL-1β
and nitric oxide (NO) through blocking the activation of
both NF-κB and MAPK pathways [22]. In mast cells, MED
can significantly suppress antigen-stimulated degranulation
and cytokine production by blocking the MAPK pathways.
Because MED displays an anti-inflammatory activity, we
wanted to determine whether it could inhibit atheros-
clerosis, which is related to the inflammatory response
[25–27]. Herein, we show that MED can inhibit foam cell
formation and cytokine production induced by ox-LDL inB
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Fig. 1 MED inhibits ox-LDL-induced foam cell formation. RAW264.7 cells w
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Results
MED significantly suppresses macrophage foam cell
formation
Foam cells are pathogenic cells in atherosclerosis that are
derived from monocytes/macrophages and vascular
smooth muscle cells. RAW264.7 cells, which share many
features in common with macrophages, can be induced to
form foam cells by ox-LDL in vitro. To explore whether
MED affected foam cell formation, RAW264.7 cells were
treated with ox-LDL in the absence or presence of different
concentrations of MED for 24 h and were then stained
with Oil-red O solution. First, we detected the cytotoxicity
of MED to RAW 264.7 cells using a MTT assay. As shown
in Fig. 1a, MED showed no cytotoxicity to RAW 264.7
cells in a concentration range between 1 and 10 μM; there-
fore, these concentrations of MED were used in the subse-
quent in vitro experiments. A total of 35 % of RAW264.7
cells displayed foamy characteristics with oil red staining of
lipid droplets after incubation with ox-LDL for 24 h, but
MED treatment significantly reduced the foam cell forma-
tion in a dose-dependent manner (Fig. 1b, c).                              +                +
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macrophages
LOX-1 is a lectin-like receptor for ox-LDL in endothelial
cells, smooth muscle cells, and macrophages, which are
three important cell types involved in the development of
atherosclerosis [10]. LOX-1 expression can be induced by
ox-LDL in a feed-forward fashion. To determine whether
MED can inhibit foam cell formation by blocking ox-LDL-
induced LOX-1 expression, RAW 264.7 cells were treated
with ox-LDL in the absence or presence of MED for 24 h;
the LOX-1 protein levels were then evaluated by western
blotting. As shown in Fig. 2a, MED significantly inhibited
the LOX-1 protein levels in a dose-dependent manner. To
determine whether the reduced expression level of LOX-1
could be attributed to the reduced mRNA levels of LOX-1,
real-time PCR was performed. As shown in Fig. 2b, MED
significantly suppressed the mRNA levels of LOX-1, which
indicated that MED may inhibit ox-LDL-induced LOX-1
expression at the transcriptional level.
MED can suppress proinflammatory cytokine expression
in macrophages induced by ox-LDL
It has been demonstrated that macrophages are abundant
in plaque lesions and play a central role in atherosclerosis
development [28]. In addition to inducing foam cell for-
mation, ox-LDL can activate macrophages to produce
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Fig. 2 MED attenuates ox-LDL-induced LOX-1 expression. RAW264.7 cells w
MED for 24 h. a LOX-1 protein levels were measured by western blot analy
indicate means ± SD from three independent experiments; *p < 0.051β, to promote atherosclerosis. To examine whether MED
could affect the ox-LDL-induced production of TNF-α,
IL-6, and IL-1β in macrophages, the production of these
cytokines by ox-LDL-stimulated macrophages was mea-
sured in the absence or presence of MED. As shown in
Fig. 3a, MED significantly inhibited the ox-LDL-induced
production of TNF-α, IL-6, and IL-1β. Furthermore, we
found that MED significantly suppressed the mRNA levels
of TNF-α, IL-6, and IL-1β in RAW 264.7 cells (Fig. 3b),
which indicated that MED might inhibit ox-LDL-induced
proinflammatory cytokine expression at the transcrip-
tional level.MED inhibits ox-LDL induced activation of NF-κB signaling
in macrophages
It has been shown that ox-LDL can induce the expression
of LOX-1 and proinflammatory cytokines, such as IL-1β
and TNF-α, through the activation of NF-κB signaling
[2, 29]. To explore whether MED could inhibit NF-κB
signaling, the effects of MED on ox-LDL-induced NF-κB
activation in RAW 264.7 cells were examined. As shown
in Fig. 4a and b, MED significantly suppressed ox-LDL-
induced IκB-α degradation, nuclear p65 expression, and
the DNA binding activity of NF-κB at concentrations of 5
and 10 μM in macrophages, which indicated that MED
could inhibit the activation of NF-κB signaling.*
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Fig. 3 MED significantly inhibits ox-LDL-induced production of TNF-α, IL-6, and IL-1β. a RAW264.7 cells were stimulated with ox-LDL in the
presence of different concentrations of MED for 24 h. The amounts of TNF-α, IL-6, and IL-1β were measured using ELISA assay kits. b The mRNA
levels of TNF-α, IL-6, and IL-1β were measured by real-time PCR. Values indicate means ± SD from three independent experiments.
**p < 0.01, *p < 0.05
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ApoE−/− mice
Because high-fat diet (HFD)-induced arterial lesions in
ApoE−/− mice have many features in common with hu-
man atherosclerosis, ApoE−/− mice are considered to be
a good animal model of atherosclerosis [30]. Because
MED could effectively inhibit ox-LDL-induced macro-
phage foam cell formation and activation in vitro, we
assessed whether MED could suppress HFD-induced
atherosclerosis in ApoE−/− mice. ApoE−/− mice were fed
with a high-fat diet, and vehicle (PBS) or MED (4 mg/kg/
day) was injected every 2 days for 2 months, then, theatherosclerotic lesions in the descending aorta were de-
tected by Sudan IV staining. As shown in Fig. 5a and b,
MED significantly suppressed the area of lesions compared
with the PBS control group, which demonstrated that MED
can suppress atherosclerosis in vivo. Additionally, we found
that there was no significant difference in body weight gain
between the PBS control group and MED group during the
8 weeks of HFD feeding (Additional file 1: Figure S1),
which indicated that MED caused no apparent toxicity in
mice after long-term MED treatment.
To determine whether MED could suppress inflamma-
tion in mice after 8 weeks of HFD feeding, the levels of
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Fig. 4 MED inhibits ox-LDL-induced activation of NF-κB signaling. a and b RAW264.7 cells were stimulated with ox-LDL in the absence or presence
of MED for 3 h, and then western blot analysis of IκB-α and nuclear p65 was performed. Representative images of three independent experiments are
shown. a, The effect of MED on ox-LDL-induced IκB-α degradation and nuclear NF-κB p65 expression. b, The effect of MED on ox-LDL-induced NF-κB
























Fig. 5 MED effectively reduces atherosclerotic lesions in HFD-fed ApoE−/− mice. a HFD-fed mice were injected with PBS or 4 mg/kg/day MED
every other day for 8 weeks, respectively. At the end points, mice were sacrificed, and atherosclerotic lesions in the descending aorta were
detected by Sudan IV staining. b Quantitative analysis of atherosclerotic lesion sizes. Data are presented as the means ± S.D;n = 5 per group. **p < 0.01
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1β, in plasma and the aortic arch of HFD-fed ApoE-
deficient mice were measured. As shown in Fig. 6a and b,
MED suppressed the protein levels of TNF-α, IL-6, and
IL-1β in plasma and the mRNA levels of TNF-α, IL-6, and
IL-1β in the aortic arch. Furthermore, MED suppressed
nuclear p65 expression in the aortic arch of HFD-fed
ApoE-deficient mice (Additional file 2: Figure 2S). These
results indicate that MED can inhibit atherosclerosis at
least in part by suppressing inflammation in vivo.
Discussion
Atherosclerosis is considered a type of chronic inflamma-
tion. The differentiation of macrophages to lipid-laden
foam cells is a pivotal process in the development of the
atherosclerosis [31]. The transformation of foam cells can
be attributed to the dysregulated uptake of modified LDL
by macrophages [32, 33]. Ox-LDL is a critical factor in the



















































Fig. 6 Inhibitory effects of MED on pro-inflammatory cytokine expression in
using ELISA assay kits. b Expression levels of the inflammatory genes, includin
arch isolated from mice; Control, normal chow-fed group; PBS, HFD-fed and P
means ± S.D; n = 5 per group; **p < 0.01, *p < 0.05foam cell formation. It is thought that uptake of ox-LDL
by macrophage scavenger receptors is largely responsible
for disease progression. As a receptor for ox-LDL, LOX-1
accumulates in human and animal atherosclerotic lesions
in vivo [34]. It has been shown that LOX-1 functions as a
proinflammatory adhesion molecule in leukocytes and
platelets [35]. LOX-1 affects several inflammatory stages
of atherosclerosis, such as macrophage foam cell forma-
tion and activation [16]. It has been reported that the dele-
tion of LOX-1 reduces atherogenesis in LDLR-knockout
mice that are fed a high cholesterol diet [36], thus
highlighting the important role of LOX-1 in atheroscler-
osis. In our present study, MED could significantly inhibit
RAW 264.7 cells transformation into foam cells and LOX-
1 expression induced by ox-LDL, which indicated that the
suppression of LOX-1 expression by MED contributes to
its inhibitory effects on macrophage foam cell formation.
It has been shown that LOX-1 is involved in infla-
































































mice. a The amounts of TNF-α, IL-6, and IL-1β in plasma were measured
g TNF-α, IL-6, and IL-1β, were measured by real-time PCR in the aortic
BS-treated group; MED, HFD-fed and MED treated group. Data indicate
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amounts of pro-inflammatory cytokines, such as TNF-α,
IL-6, and IL-1β, to promote atherosclerosis. Herein, we
have shown that MED can significantly inhibit the ox-
LDL-induced expression of TNF-α, IL-6, and IL-1β both
in RAW264.7 cells and in plaque lesion areas, which sug-
gests that MED can suppress inflammatory responses in
atherosclerosis.
NF-κB is a transcription factor involved in several in-
flammatory diseases, including atherosclerosis. The activa-
tion of NF-κB has been observed at different stages of
atherosclerosis [13]. The binding of ox-LDL to LOX-1 can
activate NF-κB signaling, thus leading to enhanced macro-
phage foam cell formation and proinflammatory cytokine
production. Our data show that MED could significantly
inhibit ox-LDL/LOX-1-induced activation of NF-κB sig-
naling, which suggests that MED inhibits macrophage
foam cell formation and activation at least in part by
blocking NF-κB signaling.
The most significant finding of this current study is
that MED could dramatically suppress atherosclerosis in
ApoE−/− mice fed a high fat diet. In addition to inhibit-
ing inflammation and foam cell formation, we found that
MED could significantly reduce the levels of blood fats,
such as total triglyceride, total cholesterol, high-density
lipoprotein, and low-density lipoprotein in mice (Additional
file 3: Figure S3). These features might all contribute to the
anti-atherogenic activity of MED. Therefore, MED exhibits
the anti-atherogenic activity both in vitro and in vivo, which
suggests that MED might represent a novel drug candidate
for the effective treatment of atherosclerosis.
Collectively, our results demonstrate that MED, a novel
marine microbial compound, can inhibit macrophage foam
cell formation and activation in vitro and suppress athero-
sclerosis in ApoE−/− mice, at least in part by inhibiting
NF-κB activation. Our findings suggest that MED repre-




MED was isolated from the fermentation broth of D. sp.
HLY-1, as previously described [19]. The identity of MED
was confirmed by HRMS and 1H and 13C NMR analysis,
and the purity of MED exceeded 95.7 % according to
HPLC analysis. MED was dissolved in dimethylsulfoxide
(DMSO) and stored at −20 °C. DMSO, MTT, oil red O,
and anti-β-actin antibody were obtained from Sigma-
Aldrich (Sigma, St. Louis, MO, USA); IL-1β ELISA kit, IL-
6 ELISA kit, and TNF-α ELISA kit were obtained from
eBioscience (eBioscience, SanDiego, CA, USA); DMEM
was purchased from Gibco (Gibco, Grand Island,NY,
USA); fetal bovine serum (FBS) was obtained from
Hyclone (Thermo Scientific, IL, USA); Ox-LDL waspurchased from Unionbiol (Beijing, China); anti-IκB-α
antibody was obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA); antibodies against p65 and PARP
were purchased from Cell Signaling Technology (Danvers,
MA, USA); antibody against LOX-1 was obtained from
R&D systems (Minneapolis, MN, USA); high-fat diet was
produced by Vital River Laboratories (Beijing, China)
according to the formula from Harlan (TD.88137).
Methods
Cell culture
Murine macrophage cell RAW 264.7 cells were purchased
from the American Type Cell Culture Collection. Cells
were cultured in DMEM supplemented with 10 % fetal
bovine serum (FBS).
Cytotoxicity assay
The cytotoxicity of MED was analyzed using a MTTassay.
A total of 7 × 103 cells/well were seeded into a 96-well
plate. After incubation with MED for 24 h, 10 μl MTT
(5 mg/ml, Sigma) was added to each well. Plates were in-
cubated for 4 h before adding of 100 μl lysis buffer (10 %
SDS in 0.01 M HCl). Absorbance was measured at
560 nm using a microplate reader.
Western blot analysis
Lysates for western blot analysis were prepared from
cells and aortic tissues. A total of 30 μg protein lysates
of each sample were subjected to SDS-PAGE and trans-
ferred onto nitrocellulose membranes. Blots were incu-
bated with appropriate specific primary antibodies
overnight at 4 °C. After washing three times for 15 min
each with TBST (TBS + 0.1 % Tween20), blots were in-
cubated with horseradish-peroxidase-conjugated second-
ary antibody (Pierce, Rockford, IL, USA) and visualized
by chemiluminescence. Band densities were quantified
by densitometry using the Scion Image software and
were normalized to the β-actin and PARP levels.
Quantitative real-time PCR
Total RNA was isolated using Trizol reagent (Invitrogen)
according to the manufacturer’s instructions. The cDNA
was synthesized from 2 μg total RNA using MMLV tran-
scriptase (ToYoBo, Shanghai, China) with random primers,
real-time PCR was performed using SYBR Premix ExTaq
(TaKaRa, Dalian, China). Quantification was normalized to
the amount of endogenous GAPDH.
Cytokine assays
Cells were seeded in 96-well plates 24 h prior to ox-LDL
and MED treatment, and the concentrations of TNF-α,
IL-6, and IL-1β were determined using ELISA kits
(eBioscience, San Diego, CA) according to the manufac-
turer’s instructions.
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(LDL), triglyceride (TG), and total cholesterol (TC)
Mice were euthanized and blood was collected. HDL,
LDL, TG, and TC were measured using ELISA kits ac-
cording to the manufacturer’s instructions.
Nuclear protein extraction
After ox-LDL and MED treatments, cells were collected
and then Buffer A (10 mM HEPES (pH 7.9), 10 mM KCl,
0.1 mM EDTA, 1 mM DTT, and 0.5 mM PMSF) was
added. After incubation on ice for 20 min, cells were sus-
pended in Buffer A with 2.5 % NP- 40, vortexed for 10 s
and then centrifuged at 12,000 × g for 5 min at 4 °C. Su-
pernatants were collected to detect cytoplasmic proteins.
Buffer B (20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM
EDTA, 1 mM DTT, and 1 mM PMSF) was used to resus-
pend the precipitates, and the suspension was vortexed
for 25 min at 4 °C and then centrifuged at 12,000 × g for
5 min at 4 °C. Supernatants were collected as nuclear ex-
tracts, and the protein concentrations were measured
using the Bradford protein assay (Bio-Rad, Hercules, CA).
Electrophoretic mobility shift assay
A total of 10 μg nuclear extract was incubated with 20 nM
biotin-labeled double- stranded oligonucleotide probes for
20 min at room temperature, and then were separated on
a non-denaturing 6 % (w/v) polyacrylamide gel. The
biotin-labeled oligonucleotide probes (NF-κB: 5′ -AGT
TGA GGG GAC TTT CCC AGG C-3′, 3′ -TCA ACT
CCC CTG AAA GGG TCC G-5′) were transferred from
the polyacrylamide gel onto a nylon membrane. Bands
were detected with a LightShift chemiluminescent EMSA
kit (Pierce, Rockford, IL) according to the manufacturer’s
instruction.
High-fat diet-induced atherosclerosis in ApoE−/− mice
Eight-week-old ApoE−/− mice were fed a high-fat diet for
12 weeks to induce atherosclerosis. All experiments were
approved by the Animal Care and Use Committee of
Xiamen University (Protocol Number: XMULAC 2012
0001). Every effort was made to reduce animal suffering.
Atherosclerotic lesion analysis
Mice were euthanized and their hearts and aortas were
isolated. The degree of atherosclerosis was assessed by
determining lesion sizes on both pinned open aortas and
serial cross-sections through the aortic root as previ-
ously described but with some modification [38–40].
The aorta was opened longitudinally along the ventral
midline from the iliac arteries to the aortic root. After
the branching vessels were treated, the aorta was pinned
out flat on a black wax surface. Lesions were treated
with 70 % ethanol and then stained with Sudan IV for
15 min, destained with 80 % ethanol, and then washedwith PBS. Aortic images were analyzed using the Adobe
Photoshop software; data are reported as the percentage
of the aortic surface covered by lesions.
Statistical analysis
Data were collected from several independent experiments,
with three replicates per experiment. All data were analyzed
by one-way Anova with post-Tukey’s post-test with the
SPSS 16.0 software package: p < 0.05 and p < 0.01 were con-
sidered to indicate statistically significant differences. Bars
in the graph represent standard deviation (S.D.).
Additional files
Additional file 1: Figure S1. There is no significant difference in body
weight change between PBS control group and MED group during
8 weeks of HFD feeding.
Additional file 2: Figure S2. Inhibitory effects of MED on NF-κB activation
in aortic arch tissue isolated from mice. Nuclear proteins were extracted from
aortic arch tissue. Nuclear NF-κB p65 was detected by Western blot.
Representative images are shown from three independent experiments.
(Control: normal chow-fed group, PBS: HFD-fed and PBS treated group, MED:
HFD-fed and MED treated group).
Additional file 3: Figure S3. MED decreases the levels of blood fats in
mice. Mice were euthanized and blood was collected. The levels of total
triglyceride, total cholesterol, high density lipoprotein, and low density
lipoprotein were measured using ELISA kits. (Control: normal chow-fed
group, PBS: HFD-fed and PBS treated group, MED: HFD-fed and MED
treated group). Values are shown as the mean ± SD from three independent
experiments. *p < 0.05vs PBS group.
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